CKD Bio Corp. | Mutual Funds
Mutual Funds that own CKD Bio Corp.
DFA Emerging Markets Core Equity Portfolio
44,956
0.86%
3,422
0%
04/30/2018
DFA Emerging Markets Small Cap Series
31,884
0.61%
0
0.01%
01/31/2018
DFA Dimensional Emerging Markets Value Fund
22,971
0.44%
0
0%
01/31/2018
Cornerstone Advisors Global Public Equity Fund
12,300
0.24%
0
0.02%
07/31/2018
TIFF Multi Asset Fund
7,675
0.15%
0
0%
06/30/2018
Cornerstone Advisors Public Alternatives Fund
7,515
0.14%
-1,344
0.02%
07/31/2018
Dimensional Funds Plc - Emerging Markets Value Fund
3,018
0.06%
14
0%
11/30/2017
Symmetry Moderate Growth Portfolio
2,992
0.06%
644
0%
06/30/2018
Symmetry Growth Portfolio
2,985
0.06%
699
0.01%
06/30/2018
DFA Emerging Markets Social Core Equity Portfolio
2,712
0.05%
864
0%
04/30/2018
| Address |
Chongkundang Building
Seoul SL 03742
Korea, Republic Of
|
|
Employees
|
- |
| Website |
http://www.ckdbio.com |
| Updated |
07/08/2019 |
| CKD Bio Corp. engages in the manufacture and sale of raw material medicine. Its products include potassium clavulanate, demeclocycline, rifampicin, and acarbose. The company was founded on November 12, 2001 and is headquartered in Seoul, South Korea. |
